Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort.
Römer T, Franzen S, Kravets H, Farrag A, Makowska A, Christiansen H, Eble MJ, Timmermann B, Staatz G, Mottaghy FM, Bührlen M, Hagenah U, Puzik A, Driever PH, Greiner J, Jorch N, Tippelt S, Schneider DT, Kropshofer G, Overbeck TR, Christiansen H, Brozou T, Escherich G, Becker M, Friesenbichler W, Feuchtinger T, Puppe W, Heussen N, Hilgers RD, Kontny U. Römer T, et al. Among authors: overbeck tr. Cancers (Basel). 2022 Feb 28;14(5):1261. doi: 10.3390/cancers14051261. Cancers (Basel). 2022. PMID: 35267570 Free PMC article.
Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas.
Wolff HA, Rödel RM, Gunawan B, Overbeck T, Herrmann MK, Hennies S, Hille A, Vorwerk H, Matthias C, Hess CF, Christiansen H. Wolff HA, et al. J Cancer Res Clin Oncol. 2010 Jan;136(1):89-97. doi: 10.1007/s00432-009-0640-2. Epub 2009 Jul 18. J Cancer Res Clin Oncol. 2010. PMID: 19618214 Free PMC article.
Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC--treatment results after long-term follow-up and literature overview.
Herrmann MK, Bloch E, Overbeck T, Koerber W, Wolff HA, Hille A, Vorwerk H, Hess CF, Muller M, Christiansen H, Pradier O. Herrmann MK, et al. Cancer Radiother. 2011 Apr;15(2):81-8. doi: 10.1016/j.canrad.2010.03.017. Epub 2010 Aug 12. Cancer Radiother. 2011. PMID: 20708424 Review.
Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice.
Guhlich M, Maag TE, Dröge LH, El Shafie RA, Hille A, Donath S, Schirmer MA, Knaus O, Nauck F, Overbeck TR, Hinterthaner M, Körber W, Andreas S, Rittmeyer A, Leu M, Rieken S. Guhlich M, et al. Among authors: overbeck tr. Strahlenther Onkol. 2022 Dec;198(12):1072-1081. doi: 10.1007/s00066-022-01952-z. Epub 2022 May 12. Strahlenther Onkol. 2022. PMID: 35552767 Free PMC article.
[Tumor Conference I].
Overbeck T, Schäper C, Griesinger F, Gröschel A, Haug A, Leschber G, Pfluger T, Pöttgen C. Overbeck T, et al. Onkologie. 2013;36 Suppl 6:2-4. doi: 10.1159/000353714. Epub 2013 Aug 12. Onkologie. 2013. PMID: 24162624 Free article. German. No abstract available.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Doebele RC, et al. Among authors: overbeck tr. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838007 Free PMC article.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WEE. Gauler TC, et al. Among authors: overbeck tr. Ann Oncol. 2012 Mar;23(3):678-687. doi: 10.1093/annonc/mdr255. Epub 2011 May 26. Ann Oncol. 2012. PMID: 21617019 Free article. Clinical Trial.
49 results